Clinical trials: GLP-1
Obesity, Overweight
The Effects of GLP-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior
The goal of this study is to explore whether of GLP-1 receptor agonist use is associated with differences in taste, smell, food preferences, appetite, food cravings, and responses to food cues in adults.
- Conditions
- Obesity, Overweight, Taste Perception, Olfaction
- Trial name
- NCT07611201
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Purdue University
Endoscopy, Digestive System, GLP1-R-related Disease
Evaluate the Detection of Retained Gastric Contents and Assess Safety Using the Flower Capsule Endoscopy in Healthy Individuals and GLP-1 Receptor Agonist Users
Clinical Study Overview Feasibility Study Plan (Study 1: Healthy Participants) Study 1- Confirming Flower capsule performance characteristics in detection of retained gastric contents greater than 1.5mL/kg in Healthy volunteers…
- Trial name
- NCT06927401
- Testing
- Flower
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Asian Institute of Gastroenterology, India
Type 1 Diabetes Mellitus
A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients
Primary Objective: To assess the tolerability and safety of SAR438544 after single ascending subcutaneous (SC) doses in healthy subjects and in type 1 diabetes mellitus (T1DM) patients.
- Trial name
- NCT02625636
- Testing
- SAR438544, r-glucagon
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors
The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion
The primary objective of the present study is to evaluate the effect of HMG-CoA reductase inhibition during 14 days on the postprandial plasma GLP-1 response in healthy individuals.
- Trial name
- NCT03018444
- Testing
- Atorvastatin
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes
Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance
The study aims to evaluate the elimination and degradation of glucagon in patients with type 2 diabetes compared to matched healthy subjects.
- Trial name
- MCR Glucagon (NCT02475421)
- Testing
- Glucagon
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Obesity, Overweight
Activity of Bioactive Natural Compounds as Potential Agonists of GLP1R
The goal of this clinical trial is to learn if natural bioactive compound jubenine works to reduce appetite and to favour weight loss. It will also learn about the safety of natural bioactive compound jubenine.
- Trial name
- BIOBESICOM (NCT06513715)
- Testing
- Control, Jubanine
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Universidad Católica San Antonio de Murcia
Adults With Simple Obesity
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
This study is a prospective, randomized, open-label clinical trial enrolling 66 adults with simple obesity who have not used weight-loss medications for at least 3 months.
- Trial name
- NCT07293325
- Testing
- Semaglutide, Tirzepatide, Metformin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diabetes Mellitus
Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin
The main goal is to study the correlation of pancreatic uptake of In-111-DTPA-exendin-4 (measured by ex vivo counting) with the beta cell mass determined in the pancreatic specimens obtained after surgery.
- Trial name
- GLP1-ex-vivo (NCT03889496)
- Testing
- indium-111-exendin SPECT/CT
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Radboud University Medical Center
Diabetes Mellitus, Type 2
Effect of Metformin and Cholecystokinin-mediated Gallbladder Emptying on GLP-1 Secretion in Type 2 Diabetes
Accumulating evidence suggests that bile acids in our intestines may constitute essential components in the complex mechanisms regulating gut hormone secretion and glucose homeostasis.
- Trial name
- NCT02497313
- Testing
- Isotonic saline, Cholecystokinin, Metformin
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 1 Diabetes
Closed-Loop Glucagon Administration For Hypoglycemia Treatment
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers glucagon only can prevent or treat hypoglycemia vs. usual care for people with type 1 diabetes > 21 years old.
- Trial name
- NCT02181127
- Testing
- Glucagon-only Bionic Pancreas
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Residual Gastric Contents, Delayed Gastric Emptying
GLP-1 RA Cessation and Gastric Ultrasound Findings
This prospective observational study will evaluate the association between the time interval since the last dose of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and residual gastric contents before elective surgery.
- Trial name
- NCT07623148
- Testing
- GLP-1 RA Cessation Interval
- Where
- South Korea
- Volunteers
- 186 people
- Sponsor
- Wonkwang University Hospital
Insulin Resistance, Satiety
Gut Hormone Response After Paleolithic-type Meals
The effects of two palaeolithic-type meals will be assessed with respect to a panel of gut hormones, satiety, blood glucose and insulin levels as compared to a meal constructed along the lines of the world Health Organisation…
- Trial name
- FooA2 (NCT01999504)
- Testing
- PAL-2, TFH-1, Reference
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Type 2 Diabetes Mellitus
Alpha-Cell Sensitivity to GLP-1 in Patients With Type 2 Diabetes
Glucagon-like peptide 1 is known to improve sensitivity of the pancreatic beta-cell. Further it inhibit secretion from the pancreatic alpha-cell by mechanisms not fully understand.
- Trial name
- NCT00497133
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Diabetes Mellitus, Type 1
Liraglutide in Newly Onset Type 1 Diabetes.
The purpose of this study is to investigate the effect and safety of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive…
- Trial name
- NewLira (NCT01879917)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 65 people
- Sponsor
- Hvidovre University Hospital
Obesity & Overweight
Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity
Glucagon-like peptide (GLP1) drugs have quickly become a standard treatment for the adults with obesity. These drugs target the appetite control center of the brain, which clows the rate of stomach emptying, and makes a person…
- Trial name
- GUT BOOST (NCT07823452)
- Testing
- gut-brain axis (GLP-1)-activating food carbohydrate
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Indiana University
Schizophrenia, Prediabetic State
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
To investigate whether the Glucagon Like Peptide 1 (GLP-1) Semaglutide (1.34 mg/ml) has preventive effect compared to placebo in the development of diabetes and Metabolic Syndrome in people with pre-diabetes, overweight and…
- Trial name
- HISTORI (NCT05193578)
- Testing
- Semaglutide, 1.34 mg/mL
- Where
- Denmark
- Volunteers
- 154 people
- Sponsor
- Jan Frystyk
Diabetes Mellitus Type 2
Effects on Remission of Type 2 Diabetes Mellitus Following Gastric Bypass Alone vs Gastric Bypass Combined With Truncal Vagotomy
This randomized, triple-blind clinical trial investigates whether adding truncal vagotomy to Roux-en-Y gastric bypass (RYGB) enhances remission of type 2 diabetes mellitus (T2DM) in patients with obesity.
- Trial name
- VagusSx (NCT07278115)
- Testing
- Roux-en-Y Gastric Bypass plus Truncal Vagotomy, Roux-en-Y Gastric Bypass
- Where
- 2 sites in Greece
- Volunteers
- 40 people
- Sponsor
- University Research Institute for the Study of Genetic & Malignant Disorders in Childhood
Type 2 Diabetes
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.
- Trial name
- NCT06716424
- Testing
- iGlarLixi (insulin glargine/lixisenatide)
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Sanofi
Diabetes (DM)
Studies of Insulin and Glucagon Action in the Liver
This study examines how glucagon works to regulate glucose metabolism, based on new findings that suggest glucagon signaling in the liver has more than one role, and that these multiple roles can be opposing in nature.
- Trial name
- SIGNAL (NCT07300982)
- Testing
- Glucagon
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Duke University
Type 1 Diabetes
Closed-loop Control of Overnight Glucose Levels in Adults and Adolescents With Type 1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's…
- Trial name
- NCT01905020
- Testing
- Carbohydrate-rich meal, Exercise
- Where
- 3 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Institut de Recherches Cliniques de Montreal